Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy

Clinical and Experimental Allergy

Volumn 36, Issue 4, 2006, Pages 465-474

  Tarzi, M ^a   Klunker, S ^a,b   Texier, C ^c   Verhoef, A ^a   Stapel, S O ^c   Akdis, C A ^b   Maillere, B ^c   Kay, A B ^a   Larche M ^a,d  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^b SWISS INSTITUTE OF ALLERGY AND ASTHMA RESEARCH SIAF   (Switzerland)

^c CEA SACLAY   (France)

^d CLB Sanguin ^*  (Netherlands)

Author keywords

Allergy; Cytokine; Epitope; Human; Immunotherapy; T cells; Tolerance suppression anergy; Transcription factors

Indexed keywords

ALLERGEN; BEE VENOM; CYTOKINE; EPITOPE; GAMMA INTERFERON; HLA DR ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 13; PEPTIDE; PHOSPHOLIPASE A2; SUPPRESSOR OF CYTOKINE SIGNALING 3; VACCINE;

ADULT; ANTIBODY SPECIFICITY; ARTICLE; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DELAYED HYPERSENSITIVITY; DISEASE MARKER; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; HONEYBEE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INSECT ALLERGY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN INDUCTION; SKIN ALLERGY; SKIN MANIFESTATION; T LYMPHOCYTE; TRANSCRIPTION REGULATION;

ADULT; BEE VENOMS; CELL DIVISION; CYTOKINES; DRUG HYPERSENSITIVITY; EPITOPES, T-LYMPHOCYTE; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION; HLA-DR ANTIGENS; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRADERMAL; INTERLEUKIN-10; INTERLEUKIN-13; LEUKOCYTES, MONONUCLEAR; MALE; PEPTIDES; PHOSPHOLIPASES A; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME;

EID: 33645301858     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2006.02469.x     Document Type: Article

References (34)

1. Walker SM Varney VA Gaga M Jacobson MR Durham SR. Grass pollen immunotherapy efficacy and safety during a 4-year follow-up study. Allergy 1995 50 405 13.
2. Durham SR Walker SM Varga EM et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999 341 468 75.
3. Hunt KJ Valentine MD Sobotka AK Benton AW Amodio FJ Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978 299 157 61.
4. Varney VA Edwards J Tabbah K Brewster H Mavroleon G Frew AJ. Clinical efficacy of specific immunotherapy to cat dander a double-blind placebo-controlled trial. Clin Exp Allergy 1997 27 860 7.
5. Abramson M Puy R Weiner J. Immunotherapy in asthma an updated systematic review. Allergy 1999 54 1022 41.
6. Tarzi M Larche M. Peptide immunotherapy for allergic disease. Exp Opin Biol Ther 2003 3 617 26.
7. Carballido JM Carballido-Perrig N Kagi MK et al. T cell epitope specificity in human allergic and nonallergic subjects to bee venom phospholipase A2. J Immunol 1993 150 8 Pt 1 3582 91.
8. Muller U Akdis CA Fricker M et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998 101 6 Pt 1 747 54.
9. Norman PS Ohman JL Long AA et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996 154 6 Pt 1 1623 8.
10. Marcotte GV Braun CM Norman PS et al. Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol 1998 101 4 Pt 1 506 13.
11. Pene J Desroches A Paradis L et al. Immunotherapy with Fel d 1 peptides decreases IL-4 release by peripheral blood T cells of patients allergic to cats. J Allergy Clin Immunol 1998 102 4 Pt 1 571 8.
12. Maguire P Nicodemus C Robinson D Aaronson D Umetsu DT. The safety and efficacy of ALLERVAX CAT in cat allergic patients. Clin Immunol 1999 93 222 31.
13. Simons FE Imada M Li Y Watson WT HayGlass KT. Fel d 1 peptides effect on skin tests and cytokine synthesis in cat-allergic human subjects. Int Immunol 1996 8 1937 45.
14. Oldfield WL Larche M Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats a randomised controlled trial. Lancet 2002 360 47 53.
15. Fellrath JM Kettner A Dufour N et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides results of a phase I trial. J Allergy Clin Immunol 2003 111 854 61.
16. Doolan DL Southwood S Chesnut R et al. HLA-DR-promiscuous T cell epitopes from Plasmodium falciparum pre-erythrocytic-stage antigens restricted by multiple HLA class II alleles. J Immunol 2000 165 1123 37.
17. Texier C Pouvelle S Busson M et al. HLA-DR restricted peptide candidates for bee venom immunotherapy. J Immunol 2000 164 3177 84.
18. Alexander WS. Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2002 2 410 6.
19. Egwuagu CE Yu CR Zhang M Mahdi RM Kim SJ Gery I. Suppressors of cytokine signaling proteins are differentially expressed in Th1 and Th2 cells implications for Th cell lineage commitment and maintenance. J Immunol 2002 168 3181 7.
20. Seki Y Inoue H Nagata N et al. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med 2003 9 1047 54.
21. Fontenot JD Gavin MA Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003 4 330 6.
22. Hori S Nomura T Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 1057 61.
23. Walker MR Kasprowicz DJ Gersuk VH et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+. J Clin Invest 2003 112 1437 43.
24. Aalberse RC Dieges PH Knul-Bretlova V Vooren P Aalbers M Van Leeuwen J. IgG4 as a blocking antibody. Clin Rev Allergy 1983 1 289 302.
25. van Toorenenbergen AW Aalberse RC. IgG4 and passive sensitization of basophil leukocytes. Int Arch Allergy Appl Immunol 1981 65 432 40.
26. Position paper Immunotherapy with hymenoptera venoms. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993 48 14 Suppl. 36 46.
27. Nasser S Ying S Meng Q Kay AB Ewan P. Interleukin 10 levels increase in cutaneous biopsies of patients undergoing venom immunotherapy. Eur J Immunol 2001 31 3704 13.
28. Akdis CA Blesken T Akdis M Wuthrich B Blaser K. Role of interleukin 10 in specific immunotherapy. J Clin Invest 1998 102 98 106.
29. Akdis CA Blaser K. IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines two key steps in specific immunotherapy. FASEB J 1999 13 603 9.
30. Smith TR Alexander C Kay AB Larche M Robinson DS. Cat allergen peptide immunotherapy reduces CD4 T cell responses to cat allergen but does not alter suppression by CD4 CD25T cells a double-blind placebo-controlled study. Allergy 2004 59 1097 101.
31. Yamamoto K Yamaguchi M Miyasaka N Miura O. SOCS-3 inhibits IL-12-induced STAT4 activation by binding through its SH2 domain to the STAT4 docking site in the IL-12 receptor beta2 subunit. Biochem Biophys Res Commun 2003 310 1188 93.
32. Cassatella MA Gasperini S Bovolenta C et al. Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils evidence for an IL-10-induced pathway that is independent of STAT protein activation. Blood 1999 94 2880 9.
33. Ito S Ansari P Sakatsume M et al. Interleukin-10 inhibits expression of both interferon alpha- and interferon gamma-induced genes by suppressing tyrosine phosphorylation of STAT1. Blood 1999 93 1456 63.
34. Wachholz PA Soni NK Till SJ Durham SR. Inhibition of allergen-IgE binding to B cells by IgG antibodies after grass pollen immunotherapy. J Allergy Clin Immunol 2003 112 915 22.